Recent Company News

• 01:24 AM ET Apr 30, 2025
  

  Swedish Orphan Biovitrum upgraded to buy from hold at Kepler Cheuvreux (SEK 292.20, 0.00)

• 04:30 AM ET Apr 09, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:28 AM ET Apr 29, 2025
  

  StreetAccount Metrics Recap - Swedish Orphan Biovitrum Q1 Earnings (SEK 279.20, 0.00)

• 02:05 AM ET Apr 29, 2025
  

  Swedish Orphan Biovitrum reports Q1 adj. EPS SEK2.72 vs StreetAccount SEK2.17 (SEK 279.20, 0.00)

• 10:27 AM ET Apr 28, 2025
  

  StreetAccount Consensus Metrics Preview - Swedish Orphan Biovitrum Q1 Earnings (SEK 280.00, +2.40)

• 01:07 AM ET Apr 23, 2025
  

  Swedish Orphan Biovitrum presents new and updated outcomes and analyses from XTEND phase 3 clinical program testing effectiveness of Altuvoct treatment for haemophilia A at WFH 2025 Comprehensive Care Summit (SEK 265.40, 0.00)

• 10:02 PM ET Apr 08, 2025
  

  Follow-up: US President Donald Trump says the US will unveil "major" tariff on imports of pharmaceutical goods - NBC News

• 05:27 PM ET Apr 02, 2025
  

  NICE recommends efanesoctocog alfa (Altuvoct) for treating and preventing bleeding episodes in haemophilia A (SEK 283.00, 0.00)

• 09:06 AM ET Mar 31, 2025
  

  Swedish Orphan Biovitrum releases sustainability report (SEK 287.00, -4.80)